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Elizabeth A. WinzelerAbstract
A longitudinal analysis of malaria parasite genomes
has revealed new markers that can be used in public
health efforts to limit the spread of multidrug-resistant
malaria.development/mmv-supported-projects), their slow progressMalaria is a devastating tropical disease that can be fatal
if untreated. It is caused by protozoan pathogens of the
genus Plasmodium and is transmitted by Anopheles
mosquitoes. Up to 40% of the world’s population lives in
areas where malaria exists and, despite progress, there
were still 214 million cases of malaria and 438,000
deaths in 2015. Owing to the huge burden caused by this
disease, studies on the treatment resistance of malarial
parasites are essential and a recent longitudinal study by
Cerqueira and colleagues, published in Genome Biology
[1], is an important contribution.Controlling malaria
Given that there is no sterilizing immunity and no highly
effective vaccine that can be used against malaria, this
disease is mostly controlled with bed nets, insecticide
spraying, and chemotherapies such as artemisinin combin-
ation therapies (ACT). ACTs combine new endoperoxide-
type compounds (such as artemether or artesunate) with
older antimalarial drug classes, such as an aryl alcohol
(lumefantrine) or an aminoquinoline (e.g., piperaquine),
and provide rapid symptomatic relief. The World Health
Organization currently recommends five ACTs, including
artemether–lumefantrine, artesunate–amodiaquine, artesu-
nate–mefloquine, artesunate–sulfadoxine–pyrimethamine
(ASSP), and dihydroartemisinin–piperaquine. Unfortu-
nately, malaria parasites have known resistance to olderCorrespondence: ewinzeler@ucsd.edu
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these drugs as a monotherapy or even as a folk remedy. For
example, aminoquinolines work by the same mechanism as
quinine, which is the active ingredient in antimalarial tonic
water and Jesuit’s bark. Although new types of antimalarial
drugs are in development (https://www.mmv.org/research-
to the clinic means that current ACT developers need to
select partner drugs from a limited set of older antimalarial
compounds.Artemisinin resistance
Owing to the weaknesses of the older partner drug classes,
successful combination therapies depend on the endoper-
oxide component. Thus, when parasites that are resistant
to artemisinin monotherapy first began to appear in South-
east Asia in 2008, a worldwide effort was initiated to find
the genes that are associated with artemisinin resistance in
order to study and contain the spread of resistance. The
causative gene, kelch13, encoding an uncharacterized pro-
tein with kelch- and BTB/POZ-propeller domains (Fig. 1),
was identified using a combination of genome-wide associ-
ation studies (GWAS) [2–4] and laboratory-based in vitro
evolution [2]. Although the mechanism by which kelch13
mutations confer resistance remains poorly understood, the
introduction of kelch13 single-nucleotide variants (SNVs)
into an artemisinin-sensitive parasite line by genome edit-
ing results in artemisinin-sensitive parasites [5].
Despite these advances, the community has continued
to wonder whether mutations in kelch13 are the only de-
terminants of resistance, especially as genome-wide as-
sociation tests have shown that other parasite loci are
associated with resistance and delayed parasite clearance
[4] in Southeast Asia. In addition, there are questions as
to why the kelch13 mutations, which seem to have arisen
multiple independent times, are found primarily in para-
sites in Southeast Asia.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Homology model of the Kelch13 protein showing the positions of mutations detected in the study in a side view (left) and frontal view
(right). Mutations are located in the Kelch domain, in some cases near the central cavity (C580Y and A675Y) that is involved in protein binding.
The model was constructed using SwissModel and pdb template 4yy8.1.A
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To address these questions, an international team led by
Daniel Neafsey at the Broad Institute used a new approach.
Previous GWAS had used samples that were collected pri-
marily after resistance had emerged, but the Neafsey team
performed a longitudinal analysis, sequencing 194 parasites
from patient samples obtained from five sites in Northwest
Thailand during the period in which artemisinin resistance
emerged (2001–2014) [1]. They first identified approxi-
mately 17,000 high-quality SNVs. Then, using artemisinin-
resistance data (parasite clearance time) as a phenotype,
they performed a GWAS. The authors showed that, as ex-
pected, the strongest association signal was from kelch13,
with parasites bearing the C580Y mutant allele dominating
by the end of the surveillance period. These data beautifully
show that GWAS can indeed find a specific allele and not
just important loci.
Next, the authors sought to find potential modulatory
alleles that may have supported the emergence of kelch13
mutant alleles. Here, the data were reanalyzed with only
samples containing mutant kelch13 alleles included. Inter-
estingly, this GWAS analysis identified another variant in a
kelch-domain-containing gene on chromosome 10, which
suggests that variants in this gene, kelch10, may epistatically
modulate the artemisinin-resistance phenotype.
Finally, the authors performed a longitudinal analysis
to identify candidate background mutations that were
required for the spread of kelch13 resistance mutations.
Unlike other significant variants that were identified in
the GWAS study, kelch13 variants exhibited a temporalincrease in the frequency of the non-reference allele
(C580Y) during the period when artemisinin resistance
evolved. To identify other genes that might contribute to
resistance, the authors further analyzed their dataset and
identified other variants that, like kelch13 variants, show
an increase in non-reference allele frequency over time.
Notably, some of these variants occur in genes that be-
long to pathways thought to be involved with artemisi-
nin resistance in Plasmodium falciparum, including the
phosphoinositol signaling pathway [6] and the ubiquiti-
nation pathway [7]. The authors hypothesize that these
variants may increase the fitness of parasites that have
the kelch13 gene.
Future work
A potential weakness in Cerqueira et al.'s analysis [1] is
that it focused entirely on SNVs and did not consider
structural variants. Recently, researchers have shown
that copy number variants on chromosome 14 are asso-
ciated with resistance to piperaquine, a component of an
ACT used in Southeast Asia [8, 9]. In addition, copy
number changes in mdr1, which encodes the P. falcip-
arum multidrug resistance protein 1, confer resistance
to mefloquine, another partner drug. It is possible that
important structural variants may be located near the al-
leles that were identified in this study as being associated
with delayed parasite clearance, and that the structural
variants are actually responsible for the association sig-
nal. This possibility highlights the importance of obtain-
ing independent evidence (from genome-editing studies,
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in association studies.
In addition, the group was unable to confirm the role
of variants that have been identified by others. A similar
whole-genome study by Miotto et al. [10] using 1612 pa-
tient samples from 15 locations in Cambodia, Vietnam,
Laos, Thailand, Myanmar, and Bangladesh showed that
nonsynonymous variants in fd (ferredoxin), arps10
(apicoplast ribosomal protein S10), mdr2 (multidrug
resistance protein 2), and crt (chloroquine resistance
transporter) were associated with artemisinin resistance.
Cerqueira and colleagues [1] could not confirm the role of
these variants, perhaps because the parasites in Western
Thailand are different from those that have been studied
by the Miotto group. It is also worth noting that different
partner drugs are used in different countries in Southeast
Asia.
What does this mean for malaria control?
The study provides immediate benefits to patients. Bac-
terial drug-sensitivity assays are routinely performed in
clinics throughout the world, but assessing whether a
patient has an artemisinin-resistant malaria infection is
much more challenging. Parasites from patients often do
not adapt to in vitro cell culture, and even if they do, the
resistance phenotype can be subtle and very difficult to
quantify. The new kelch13 alleles identified in this study
can now be incorporated into PCR-based tests that are
much easier and less expensive to perform than existing
tests. The results of such PCR tests can then be used to
further guide therapy practices, for example, informing
the duration or concentration of drug treatments. Know-
ledge of new resistance-conferring alleles will also help
with surveillance. If ongoing genomic surveillance shows
that the alleles are appearing in a new geographical re-
gion, more aggressive use of insecticides and bed nets
would be warranted.
The importance of limiting artemisinin resistance in
Southeast Asia cannot be underestimated, especially now
that resistance to partner drugs has emerged. If the resist-
ance alleles were to remain confined to Southeast Asia, a
great increase in morbidity and mortality would be
avoided. In fact, the World Health Organization has pro-
posed attempts to eliminate malaria in this region in order
to contain resistance. Luckily, the vast majority of malaria
cases are in Sub-Saharan Africa, where clinical trials are
showing that ACTs remain effective for now.
While Cerqueira et al.'s study [1] will be of most interest
to malaria researchers, physicians, and patients, it will also
be of broader interest to those outside of the field because
it demonstrates how whole-genome sequencing, GWAS,
and longitudinal studies can be used to provide an under-
standing of emerging drug resistance in eukaryotic patho-
gens and to identify causative alleles precisely.Abbreviations
ACT: artemisinin combination therapies; GWAS: genome-wide association
studies; SNV: single-nucleotide variant
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